Postoperative Schmerztherapie – Der Einsatz von COX–2–Inhibitoren

Zusammenfassung

Antiinflammatorisch wirksame Medikamente sind eine der bestdokumentierten Komponenten multimodaler postoperativer Analgesie. NSAR und COX–2–Inhibitoren sind hier gleichermaßen wirksam, jedoch reduziert der Einsatz der COX–2–Inhibitoren das Risiko gastrointestinaler Ulzerationen, erhöhter Blutungsneigung und Bronchospasmen. Das Risiko kardiovaskulärer und renaler Komplikationen wird durch den Einsatz von COX–2–Inhibitoren gegenüber NSAR nicht erhöht.

Summary

Compounds with anti–inflammatory properties are an important component of multimodal postoperative analgesia. NSAIDs and selective COX–2 inhibitors are of similar analgesic efficacy in this indication. However, the use of COX–2 inhibitors reduces the risk of gastrointestinal ulcers, bleeding complications and bronchospasm in comparison to NSAIDs. In parallel, COX–2 Inhibitors do not carry an increased risk of cardiovascular complications and require the same caution with regard to renal effects as NSAIDs.

Multimodale Analgesie - NSAR - COX–2–Inhibitoren

Multimodal analgesia - NSAIDs - COX–2 Inhibitors

Kernaussagen

• Multimodale Analgesie beschreibt den Einsatz einer Kombination mehrerer Analgetika, die verschiedene Wirkmechanismen haben oder an

• verschiedenen Stellen im Nervensystem in die Schmerzleitung eingreifen.

• Medikamente mit antiinflammatorischer Wirkung (NSAR und COX–2–Inhibitoren) sind eine effektive Komponente multimodaler Analgesie. Sie verbessern die Analgesie, sind opioidsparend und reduzieren opioidbedingte Nebenwirkungen.

• NSAR und COX–2–Inhibitoren haben eine ähnliche analgetische Wirksamkeit.

• COX–2–Inhibitoren reduzieren gegenüber NSAR in der postoperativen Schmerztherapie das Risiko von gastrointestinalen Ulzerationen, Blutungen, Asthma und möglicherweise verschlechterter Frakturheilung.

• Der kurzfristige Einsatz von COX–2–Inhibitoren in der perioperativen Phase erhöht des Risiko kardiovaskulärer Komplikationen nicht.

• Bezüglich renaler Nebenwirkungen verhalten sich NSAR und COX–2–Inhibitoren ähnlich.

Literaturverzeichnis:

• 1 Kehlet H, Dahl JB.. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment.  Anesth Analg. 1993;  77 1048-1056
• 2 Buvanendran A, Kroin JS.. Multimodal analgesia for controlling acute postoperative pain.  Curr Opin Anaesthesiol. 2009;  22 588-593
• 3 Marret E, Kurdi O, Zufferey P, Bonnet F.. Effects of nonsteroidal antiinflammatory drugs on patient–controlled analgesia morphine side effects: meta–analysis of randomized controlled trials.  Anesthesiology. 2005;  102 1249-1260
• 4 Vane JR, Botting RM.. Mechanism of action of anti–inflammatory drugs.  Scandinavian Journal of Rheumatology Supplement. 1996;  25 9-21
• 5 Romsing J, Moiniche S.. A systematic review of COX–2 inhibitors compared with traditional NSAIDs, or different COX–2 inhibitors for post–operative pain.  Acta Anaesthesiol Scand. 2004;  48 525-546
• 6 Lloyd R, Derry S, Moore RA, McQuay HJ.. Intravenous or intramuscular parecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009
• 7 Clarke R, Derry S, Moore RA, McQuay HJ.. Single dose oral etoricoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2009
• 8 Derry S, Barden J, McQuay HJ, Moore RA.. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev 2008
• 9 Gan TJ, Joshi GP, Zhao SZ, Hanna DB, Cheung RY, Chen C.. Presurgical intravenous parecoxib sodium and follow–up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid–related adverse effects.  Acta Anaesthesiol Scand. 2004;  48 1194-1207
• 10 Viscusi ER, Gimbel JS, Halder AM, Snabes M, Brown MT, Verburg KM.. A multiple–day regimen of parecoxib sodium 20 mg twice daily provides pain relief after total hip arthroplasty.  Anesth Analg. 2008;  107 652-660
• 11 Huang YM, Wang CM, Wang CT, Lin WP, Horng LC, Jiang CC.. Perioperative celecoxib administration for pain management after total knee arthroplasty – a randomized, controlled study.  BMC Musculoskelet Disord. 2008;  9 77
• 12 Harris SI, Kuss M, Hubbard RC, Goldstein JL.. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase–2–specific inhibitor, compared with ketorolac, naproxen, and placebo.  Clin Ther. 2001;  23 1422-1428
• 13 Stoltz RR, Harris SI, Kuss ME, LeComte D, Talwalker S, Dhadda S. et al. . Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects.  Am J Gastroenterol. 2002;  97 65-71
• 14 Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD.. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.  Aliment Pharmacol Ther. 2003;  18 125-132
• 15 Harris SI, Stoltz RR, LeComte D, Hubbard RC.. Parecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects.  J Clin Gastroenterol. 2004;  38 575-580
• 16 Moiniche S, Romsing J, Dahl JB, Tramer MR.. Nonsteroidal antiinflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review.  Anesth Analg. 2003;  96
• 17 Merry AF, Webster CS, Holland RL, Middleton NG, Schug SA, James M. et al. . Clinical tolerability of perioperative tenoxicam in 1001 patients – a prospective, controlled, double–blind, multi–centre study.  Pain. 2004;  111 313-322
• 18 Noveck RJ, Laurent A, Kuss M, Talwalker S, Hubbard RC.. Parecoxib sodium does not impair platelet function in healthy elderly and non–elderly individuals: Two randomised, controlled trials.  Clinical Drug Investigation.. 2001;  21 465-476
• 19 Hegi TR, Bombeli T, Seifert B, Baumann PC, Haller U, Zalunardo MP. et al. . Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac.  Br J Anaesth. 2004;  92 523-531
• 20 West PM, Fernandez C.. Safety of COX–2 inhibitors in asthma patients with aspirin hypersensitivity.  Ann Pharmacother. 2003;  37 1497-1501
• 21 Boursinos LA, Karachalios T, Poultsides L, Malizos KN.. Do steroids, conventional non–steroidal anti–inflammatory drugs and selective Cox–2 inhibitors adversely affect fracture healing?.  Journal of musculoskeletal & neuronal interactions. 2009;  9 44-52
• 22 Glassman SD, Rose SM, Dimar JR, Puno RM, Campbell MJ, Johnson JR.. The effect of postoperative nonsteroidal anti–inflammatory drug administration on spinal fusion.  Spine. 1998;  23 834-838
• 23 Park SY, Moon SH, Park MS, Oh KS, Lee HM.. The effects of ketorolac injected via patient controlled analgesia postoperatively on spinal fusion.  Yonsei medical journal. 2005;  46 245-251
• 24 Reuben SS, Ekman EF.. The effect of cyclooxygenase–2 inhibition on analgesia and spinal fusion.  J Bone Joint Surg Am. 2005;  87 536-542
• 25 Shafer SL.. Tattered threads.  Anesth Analg. 2009;  108 1361-1363
• 26 Reuben SS, Ablett D, Kaye R.. High dose nonsteroidal anti–inflammatory drugs compromise spinal fusion.  Can J Anaesth. 2005;  52 506-512
• 27 Holte K, Andersen J, Jakobsen DH, Kehlet H.. Cyclo–oxygenase 2 inhibitors and the risk of anastomotic leakage after fast–track colonic surgery.  Br J Surg. 2009;  96 650-654
• 28 Scharfenberg M, Raue W, Junghans T, Schwenk W.. "Fast–track" rehabilitation after colonic surgery in elderly patients – is it feasible?.  International journal of colorectal disease. 2007;  22 1469-1474
• 29 Klein M, Andersen LP, Harvald T, Rosenberg J, Gogenur I.. Increased risk of anastomotic leakage with diclofenac treatment after laparoscopic colorectal surgery.  Digestive surgery. 2009;  26 27-30
• 30 Rosenberg J, Harvald T.. Severe complications with diclofenac after colonic resection.  Diseases of the colon and rectum. 2007;  50
• 31 Warner TD, Mitchell JA.. COX–2 selectivity alone does not define the cardiovascular risks associated with non–steroidal anti–inflammatory drugs.  Lancet. 2008;  371 270-273
• 32 Chang IJ, Harris RC.. Are all COX–2 inhibitors created equal?.  Hypertension. 2005;  45 178-180
• 33 Moore RA, Derry S, McQuay HJ.. Cyclo–oxygenase–2 selective inhibitors and nonsteroidal anti–inflammatory drugs: balancing gastrointestinal and cardiovascular risk.  BMC Musculoskelet Disord. 2007;  8 73
• 34 Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL. et al. . Complications of the COX–2 inhibitors parecoxib and valdecoxib after cardiac surgery.  N Engl J Med. 2005;  352 1081-1091
• 35 Borgdorff P, Tangelder GJ, Paulus WJ.. Cyclooxygenase–2 inhibitors enhance shear stress–induced platelet aggregation.  J Am Coll Cardiol. 2006;  48 817-823
• 36 Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK. et al. . Safety and efficacy of the cyclooxygenase–2 inhibitors parecoxib and valdecoxib after noncardiac surgery.  Anesthesiology. 2006;  104 518-526
• 37 Schug SA, Joshi GP, Camu F, Pan S, Cheung R.. Cardiovascular safety of the cyclooxygenase–2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.  Anesth Analg. 2009;  108 299-307
• 38 Harris Jr. RC. Cyclooxygenase–2 inhibition and renal physiology.  Am J Cardiol. 2002;  89
• 39 Lee A, Cooper MG, Craig JC, Knight JF, Keneally JP.. Effects of nonsteroidal anti–inflammatory drugs on postoperative renal function in adults with normal renal function.  Cochrane Database Syst Rev.. 2007;  2